Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients

Highlights

• Intravoxel incoherent motion may predict response to breast neoadjuvant treatment.

• Histogram analysis amplifies IVIM by quantifying spatial heterogeneity.

• Pseudodiffusvity (D_p) showed the highest potential for response prediction.

Abstract

Objective

To examine the prognostic capabilities of intravoxel incoherent motion (IVIM) metrics and their ability to predict response to neoadjuvant treatment (NAT). Additionally, to observe changes in IVIM metrics between pre- and post-treatment MRI.

Methods

This IRB-approved, HIPAA-compliant retrospective study observed 31 breast cancer patients (32 lesions). Patients underwent standard bilateral breast MRI along with diffusion-weighted imaging before and after NAT. Six patients underwent an additional IVIM-MRI scan 12–14 weeks after initial scan and 2 cycles of treatment. In addition to apparent diffusion coefficients (ADC) from monoexponential decay, IVIM mean values (tissue diffusivity D_t, perfusion fraction f_p, and pseudodiffusivity D_p) and histogram metrics were derived using a biexponential model. An additional filter identified voxels of highly vascular tumor tissue (VTT), excluding necrotic or normal tissue. Clinical data include histology of biopsy and clinical response to treatment through RECIST assessment. Comparisons of treatment response were made using Wilcoxon rank-sum tests.

Results

Average, kurtosis, and skewness of pseudodiffusion D_p significantly differentiated RECIST responders from nonresponders. ADC and D_t values generally increased (∼70%) and VTT% values generally decreased (∼20%) post-treatment.

Conclusion

D_p metrics showed prognostic capabilities; slow and heterogeneous pseudodiffusion offer poor prognosis. Baseline ADC/D_t parameters were not significant predictors of response. This work suggests that IVIM mean values and heterogeneity metrics may have prognostic value in the setting of breast cancer NAT.